Cambrex to inject $ 30 million into expansion of its manufacturing site in North Carolina
Cambrex plans to spend $ 30 million to expand small-batch manufacturing capacity at its High Point, NC plant, as the New Jersey-based CDMO continues to march into the United States to ensure production. onshore ‘of key pharmaceuticals.
The company said its most recent expansion will focus on the small molecule sector which provides drugs, drug products and testing services and will create 78 new jobs over the next three years.
“Through the commitment of our High Point team to providing our customers with world-class technical expertise, innovative chemical and engineering solutions, the plant has experienced rapid growth in demand for our development and engineering services. manufacturing, ”said Thomas Loewald, CEO of Cambrex. A declaration.
RELATED: Cambrex Seeks To Meet Demand For Onshore API Manufacturing With $ 50 Million Expansion In Iowa
Late last year, Cambrex pledged $ 50 million to build four active pharmaceutical ingredient facilities at its small molecule manufacturing site in Charles City, Iowa, which would increase capacity by 30%. . These additions were expected to be ready to go by early 2022.
In the wake of the COVID-19 pandemic, alarms have started ringing, especially among lawmakers, about the heavy reliance of the US pharmaceutical supply chain on APIs and intermediates made primarily in China. and in India. The concern was further amalgamated by political tensions between Washington and China.
As a result, more than $ 1 billion in federal funding as well as a wave of investment from the pharmaceutical industry has gone to U.S. manufacturing capabilities and their ability to provide security of supply.